 | |
 Headquarters in Otemachi, Chiyoda, Tokyo | |
| Company type | Public (K.K) |
|---|---|
| TYO: 4151 Nikkei 225 Component | |
| Industry | |
| Founded | July 1, 1949 |
| Headquarters | Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100–8185, Japan |
Key people | Nobuo Hanai, (CEO and President) |
| Products | |
| Revenue | $ 2.99 billion USD (FY 2022)
 (¥ 398.4 billion JPY) (FY 2022) |
| $ 375 million USD (FY 2022)
(¥ 53.6 billion JPY) (FY 2022) | |
Number of employees | 7,532 (consolidated) (as of December 31, 2017) |
| Parent | Kirin Holdings Company, Limited |
| Subsidiaries | 47 (33 in Japan and 14 overseas countries) |
| Website | Official website |
| Footnotes / references [1][2][3] | |
Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4][5]
- ^ "Kyowa Hakko Kirin Company Overview". Kyowa Hakko Kirin. Retrieved March 14, 2014.
- ^ "Kyowa Hakko Kirin Corporate Profile" (PDF). Kyowa Hakko Kirin. Retrieved March 14, 2014.
- ^ "Kyowa Hakko Kirin Annual Report 2012". Kyowa Hakko Kirin. Retrieved March 14, 2014.
- ^ "Components:Nikkei Stock Average". Nikkei Inc. Retrieved January 20, 2015.
- ^ "Top 50 Pharma Companies by 2012 Revenue". Wildwood Ventures Ltd. Archived from the original on February 8, 2014. Retrieved March 14, 2014.